Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 145.48
(1.29%)
INR 145.48
(1.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.11 Billion INR | -92.89% |
| 2022 | -2.14 Billion INR | -9.16% |
| 2021 | -1.96 Billion INR | -34.96% |
| 2020 | -1.45 Billion INR | 53.68% |
| 2019 | -3.14 Billion INR | -107.05% |
| 2018 | -1.52 Billion INR | 39.34% |
| 2017 | -2.5 Billion INR | -91.09% |
| 2016 | -1.31 Billion INR | -87.08% |
| 2015 | -701.47 Million INR | -67.29% |
| 2014 | -419.31 Million INR | -238.77% |
| 2013 | 302.16 Million INR | 253.5% |
| 2012 | -196.85 Million INR | 73.06% |
| 2011 | -730.77 Million INR | -772.91% |
| 2010 | -83.71 Million INR | 60.5% |
| 2009 | -211.93 Million INR | -73.03% |
| 2008 | -122.48 Million INR | -164.75% |
| 2007 | -46.26 Million INR | -151.65% |
| 2006 | -18.38 Million INR | 0.0% |
| 2005 | - INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -965 Million INR | 11.39% |
| 2024 Q2 | -1.06 Billion INR | -9.92% |
| 2023 Q4 | -1.08 Billion INR | -9.57% |
| 2023 Q3 | -993.9 Million INR | -15.36% |
| 2023 Q2 | -861.6 Million INR | 9.39% |
| 2023 Q1 | -950.9 Million INR | -16.28% |
| 2023 FY | -4.14 Billion INR | -92.89% |
| 2022 Q3 | 130.8 Million INR | 119.96% |
| 2022 Q1 | -809 Million INR | -17.16% |
| 2022 FY | -2.14 Billion INR | -9.16% |
| 2022 Q4 | -817.8 Million INR | -725.23% |
| 2022 Q2 | -655.4 Million INR | 18.99% |
| 2021 Q2 | -577.1 Million INR | -1.6% |
| 2021 Q4 | -690.5 Million INR | -398.56% |
| 2021 Q1 | -568 Million INR | -7.11% |
| 2021 Q3 | -138.5 Million INR | 76.0% |
| 2021 FY | -1.96 Billion INR | -34.96% |
| 2020 Q2 | -851.5 Million INR | -246.81% |
| 2020 Q3 | -657.2 Million INR | 22.82% |
| 2020 FY | -1.45 Billion INR | 53.68% |
| 2020 Q4 | -530.31 Million INR | 19.31% |
| 2020 Q1 | 580 Million INR | 160.07% |
| 2019 Q4 | -965.54 Million INR | -72.54% |
| 2019 Q3 | -559.6 Million INR | 14.13% |
| 2019 FY | -3.14 Billion INR | -107.05% |
| 2019 Q1 | -972.7 Million INR | -1288.08% |
| 2019 Q2 | -651.7 Million INR | 33.0% |
| 2018 FY | -1.52 Billion INR | 39.34% |
| 2018 Q1 | -656.9 Million INR | -39.74% |
| 2018 Q3 | -723 Million INR | -912.61% |
| 2018 Q4 | -70.07 Million INR | 90.31% |
| 2018 Q2 | -71.4 Million INR | 89.13% |
| 2017 Q4 | -470.1 Million INR | 21.9% |
| 2017 FY | -2.5 Billion INR | -91.09% |
| 2017 Q3 | -601.9 Million INR | 5.27% |
| 2017 Q2 | -635.4 Million INR | 20.59% |
| 2017 Q1 | -800.2 Million INR | -122.4% |
| 2016 Q1 | -380.7 Million INR | -259.15% |
| 2016 FY | -1.31 Billion INR | -87.08% |
| 2016 Q4 | -359.8 Million INR | 47.98% |
| 2016 Q3 | -691.6 Million INR | -721.38% |
| 2016 Q2 | 111.3 Million INR | 129.24% |
| 2015 Q3 | -409.2 Million INR | -130.02% |
| 2015 Q4 | -106 Million INR | 74.1% |
| 2015 FY | -701.47 Million INR | -67.29% |
| 2015 Q1 | -18.1 Million INR | 80.71% |
| 2015 Q2 | -177.9 Million INR | -882.87% |
| 2014 Q3 | -197.8 Million INR | -841.9% |
| 2014 Q1 | -111 Million INR | -109.68% |
| 2014 Q4 | -93.81 Million INR | 52.57% |
| 2014 FY | -419.31 Million INR | -238.77% |
| 2014 Q2 | -21 Million INR | 81.08% |
| 2013 Q3 | 344.1 Million INR | 499.19% |
| 2013 Q1 | 97.2 Million INR | -78.55% |
| 2013 FY | 302.16 Million INR | 253.5% |
| 2013 Q4 | -52.93 Million INR | -115.38% |
| 2013 Q2 | -86.2 Million INR | -188.68% |
| 2012 Q2 | -235.9 Million INR | -28.35% |
| 2012 Q1 | -183.8 Million INR | 16.67% |
| 2012 FY | -196.85 Million INR | 73.06% |
| 2012 Q4 | 453.14 Million INR | 295.32% |
| 2012 Q3 | -232 Million INR | 1.65% |
| 2011 FY | -730.77 Million INR | -772.91% |
| 2011 Q4 | -220.57 Million INR | -20.01% |
| 2011 Q3 | -183.8 Million INR | 0.0% |
| 2010 FY | -83.71 Million INR | 60.5% |
| 2009 FY | -211.93 Million INR | -73.03% |
| 2008 FY | -122.48 Million INR | -164.75% |
| 2007 FY | -46.26 Million INR | -151.65% |
| 2006 FY | -18.38 Million INR | 0.0% |
| 2005 FY | - INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 171.465% |
| Hester Biosciences Limited | 364.77 Million INR | 1228.119% |
| Aarti Drugs Limited | 7.14 Billion INR | 157.563% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 231.55% |
| Albert David Limited | 1.33 Billion INR | 408.368% |
| Alembic Limited | 767.77 Million INR | 635.973% |
| Alkem Laboratories Limited | 19.46 Billion INR | 121.144% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | 1831.475% |
| Bajaj HealthCare Limited | - INR | Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | 20021.771% |
| Brooks Laboratories Limited | -72.25 Million INR | -5595.401% |
| Eris Lifesciences Limited | 5.18 Billion INR | 179.415% |
| FDC Limited | 3.03 Billion INR | 235.643% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 145.829% |
| Gufic Biosciences Limited | 2.89 Billion INR | 242.202% |
| Hikal Limited | 1.49 Billion INR | 375.401% |
| Ind-Swift Limited | 1.22 Billion INR | 435.658% |
| Innova Captab Limited | 2.53 Billion INR | 262.431% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 183.263% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | 2022.557% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 179.303% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | 315.862% |
| Lupin Limited | 27.75 Billion INR | 114.825% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | 15086.674% |
| Medico Remedies Limited | 277.11 Million INR | 1584.942% |
| Morepen Laboratories Limited | 4.17 Billion INR | 198.591% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 205.769% |
| Orchid Pharma Limited | 2.36 Billion INR | 274.287% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 247.704% |
| RPG Life Sciences Limited | 2.29 Billion INR | 279.516% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | 2077.91% |
| Sigachi Industries Limited | 1.47 Billion INR | 379.195% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | -6.804% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 189.309% |
| Themis Medicare Limited | 1.3 Billion INR | 415.787% |
| Unichem Laboratories Limited | - INR | Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | 65480.378% |
| Wanbury Limited | 1.7 Billion INR | 341.039% |
| Windlas Biotech Limited | 1.29 Billion INR | 416.812% |
| ZIM Laboratories Limited | 1.09 Billion INR | 474.737% |
| Ind-Swift Laboratories Limited | 2 Billion INR | 304.827% |
| Ipca Laboratories Limited | 29.59 Billion INR | 113.904% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 103.945% |
| Venus Remedies Limited | 534.65 Million INR | 869.669% |
| Sakar Healthcare Limited | 495.5 Million INR | 930.472% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 103.938% |
| Divi's Laboratories Limited | 18.31 Billion INR | 122.474% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 191.979% |
| Mankind Pharma Limited | 40.86 Billion INR | 110.069% |
| Sequent Scientific Limited | - INR | Infinity% |
| Laurus Labs Limited | 3.94 Billion INR | 204.215% |
| Neuland Laboratories Limited | 5.31 Billion INR | 177.378% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 154.564% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 163.285% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 109.066% |
| Amrutanjan Health Care Limited | 621.02 Million INR | 762.619% |
| Wockhardt Limited | 140 Million INR | 3039.315% |
| Bal Pharma Limited | 214.56 Million INR | 2017.817% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 106.076% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 434.284% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | 846.034% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 156.953% |
| Shilpa Medicare Limited | 3.76 Billion INR | 209.397% |
| Valiant Laboratories Limited | - INR | Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 120.913% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | 145465.381% |
| Granules India Limited | 6.52 Billion INR | 163.034% |
| Medicamen Biotech Limited | - INR | Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 1750.963% |
| Piramal Enterprises Limited | - INR | Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 116.242% |
| NATCO Pharma Limited | 25.96 Billion INR | 115.85% |
| Suven Life Sciences Limited | -1.22 Billion INR | -235.696% |
| Krebs Biochemicals & Industries Limited | - INR | Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 178.745% |
| Indoco Remedies Limited | 1.52 Billion INR | 369.945% |
| Alpa Laboratories Limited | 61.51 Million INR | 6789.492% |
| Lasa Supergenerics Limited | -458 Million INR | -798.471% |